Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Associations between hyperoncotic albumin exposure and outcomes among the propensity score matched patients

From: Acute kidney injury in postoperative shock: is hyperoncotic albumin administration an unrecognized resuscitation risk factor?

Primary outcome Albumin
N = 3600
Control
N = 3600
Odds ratio (95% CI)
(albumin/control)
P value
Acute kidney injury    1.10 (1.04, 1.17) 0.002
 No injury 2610 (72.5) 2699 (75.0)   
 Stage 1 injury 729 (20.3) 704 (19.6)   
 Stage 2 injury 104 (2.9) 90 (2.5)   
 Stage 3 injury 157 (4.4) 107 (3.0)   
Secondary outcomes    Odds ratio (98.3% CI)  
Liver injury 137 (3.8) 118 (3.3) 1.16 (0.85, 1.58) 0.25
In-hospital mortality 114 (3.2) 127 (3.5) 0.88 (0.64, 1.20) 0.32
    Hazard ratio (98.3% CI)  
Length of ICU stay (h) 64 [41, 119] 50 [29, 115] 0.95 (0.90, 1.00) 0.03
  1. P value < 0.017 was considered significant (i.e., 0.05/3 = 0.017, Bonferroni correction)
  2. Discharges for those patients who died in hospital were considered as non-events and censored at the longest observed length of stay